TD Cowen raised the firm’s price target on TransMedics (TMDX) to $130 from $120 and keeps a Buy rating on the shares. The firm notes the company sailed past Q1 estimates and raised its 2025 revenue guidance by $34M. This strong performance should defuse recent dire predictions from a short-seller, TD Cowen says. On the call, TransMedics expressed confidence that it will deliver on its now higher guidance. Continued operating strength, along with progress with the next-gen programs in lung and heart, should further dent the bear thesis and help the stock, it adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $130 from $125 at Oppenheimer
- TransMedics price target raised to $125 from $105 at Piper Sandler
- TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns
- TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties
- TransMedics Reports Strong Q1 2025 Financial Results